Confronto

Eloralintide vs. VK2735

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

Peso molecolare

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Eloralintide	VK2735
Germania	Non approvato	Non approvato
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between Eloralintide and VK2735?: Eloralintide is classified as "Metabolico", while VK2735 is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or VK2735?: The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and VK2735 in Germany and the United States?: Germania: Eloralintide — Non approvato, VK2735 — Non approvato. Stati Uniti: Eloralintide — Non approvato, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

VK2735

Germania

Non approvato

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between Eloralintide and VK2735?

Eloralintide is classified as "Metabolico", while VK2735 is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or VK2735?

The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and VK2735 in Germany and the United States?

Germania: Eloralintide — Non approvato, VK2735 — Non approvato. Stati Uniti: Eloralintide — Non approvato, VK2735 — Non approvato. These are factual summaries with source and review date on the individual pages.